Genetic signature and treatment of pediatric high-grade glioma

被引:4
|
作者
Guidi, Milena [1 ]
Giunti, Laura [2 ]
Buccoliero, Anna Maria [3 ]
Caporalini, Chiara [3 ]
Censullo, Maria Luigia [1 ]
Galli, Luisa [4 ]
Genitori, Lorenzo [5 ]
Sardi, Iacopo [1 ]
机构
[1] Meyer Childrens Univ Hosp, Neurooncol Unit, Dept Pediat Oncol, 24 Viale Gaetano Pieraccini, I-50139 Florence, Italy
[2] Meyer Childrens Univ Hosp, Med Genet Unit, I-50139 Florence, Italy
[3] Meyer Childrens Univ Hosp, Pathol Unit, I-50139 Florence, Italy
[4] Univ Florence, Dept Hlth Sci, I-50139 Florence, Italy
[5] Meyer Childrens Univ Hosp, Neurosurg Unit, I-50139 Florence, Italy
关键词
glioblastoma; high-grade glioma; histone; 3; midline glioma; oncology; pediatric; BRAF V600E;
D O I
10.3892/mco.2021.2232
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pediatric high-grade glioma (HGG) is a type of malignancy that carries a poor prognosis. The genetic analysis of HGGs has previously identified useful mutations, the targeting of which has improved prognosis. Thus, further research into the more common mutations, such as H3 histone variants (HIST1H3B and H3F3A) and BRAF V600E, may be useful in identifying tumors with different prognoses, as the mutations are considered to drive two distinct oncogenic programs. The present study performed a retrospective analysis of pediatric HGGs. In total, 42 cases of HGG, including 32 cases (76.1%) of anaplastic astrocytoma and 10 cases (23.8%) of glioblastoma multiforme (GBM), were assessed. The median age of the patients was 7 years (range, 0-32 years). Mutations on histone H3, in particular the K27M and G34R mutations in the distinct variants HIST1H3B and H3F3A, in addition to the presence of the BRAF V600E mutation, were analyzed in 24 patients. The H3F3A K27M mutation was identified in 7 patients (29.1%), while the HIST1H3B K27M mutation was only observed in 1 patient with GBM. In addition, 5 patients harbored a BRAF V600E mutation (21%), while the H3F3A G34R mutation was not recorded in any of the patients. The overall survival of the wild-type patients at 20 months was 68% [confidence interval (CI): 38-85%] compared with 28% (CI: 0.4-60%) in patients with the H3F3A K27M mutation. These results suggested that patients with the H3F3A K27M mutation had a worse prognosis compared with wild-type patients (P=0.0045). Moreover, 3/5 patients with the BRAF V600E mutation had HGGs that were derived from a previous low-grade glioma (LGG; P=0.001). In conclusion, these results suggested that histone H3 mutations may help predict the outcome in patients with HGG. In addition, the BRAF V600E mutation was found to be associated with an increased risk of anaplastic progression. The novel data of the present study may help better define the clinical and radiological characteristics of glioma.
引用
收藏
页码:1 / 6
页数:6
相关论文
共 50 条
  • [1] Pediatric high-grade glioma: a review of biology, prognosis, and treatment
    Bavle, Abhishek
    Chintagumpala, Murali
    [J]. JOURNAL OF RADIATION ONCOLOGY, 2018, 7 (01) : 7 - 15
  • [2] A prognostic neural epigenetic signature in high-grade glioma
    Drexler, Richard
    Khatri, Robin
    Sauvigny, Thomas
    Mohme, Malte
    Maire, Cecile L.
    Ryba, Alice
    Zghaibeh, Yahya
    Duehrsen, Lasse
    Salviano-Silva, Amanda
    Lamszus, Katrin
    Westphal, Manfred
    Gempt, Jens
    Wefers, Annika K.
    Neumann, Julia E.
    Bode, Helena
    Hausmann, Fabian
    Huber, Tobias B.
    Bonn, Stefan
    Juetten, Kerstin
    Delev, Daniel
    Weber, Katharina J.
    Harter, Patrick N.
    Onken, Julia
    Vajkoczy, Peter
    Capper, David
    Wiestler, Benedikt
    Weller, Michael
    Snijder, Berend
    Buck, Alicia
    Weiss, Tobias
    Goeller, Pauline C.
    Sahm, Felix
    Menstel, Joelle Aline
    Zimmer, David Niklas
    Keough, Michael B.
    Ni, Lijun
    Monje, Michelle
    Silverbush, Dana
    Hovestadt, Volker
    Suva, Mario L.
    Krishna, Saritha
    Hervey-Jumper, Shawn L.
    Schueller, Ulrich
    Heiland, Dieter H.
    Haenzelmann, Sonja
    Ricklefs, Franz L.
    [J]. NATURE MEDICINE, 2024, 30 (06) : 1622 - 1635
  • [3] Molecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and Treatment
    Rizzo, Daniela
    Ruggiero, Antonio
    Martini, Maurizio
    Rizzo, Valentina
    Maurizi, Palma
    Riccardi, Riccardo
    [J]. BIOMED RESEARCH INTERNATIONAL, 2015, 2015
  • [4] Pediatric High-grade Glioma: Molecular Genetic Clues for Innovative Therapeutic Approaches
    Brian R. Rood
    Tobey J. MacDonald
    [J]. Journal of Neuro-Oncology, 2005, 75 : 267 - 272
  • [5] Pediatric high-grade glioma: Molecular genetic clues for innovative therapeutic approaches
    Rood, BR
    MacDonald, TJ
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2005, 75 (03) : 267 - 272
  • [6] Treatment of high-grade glioma in children
    Betul Cakir, Fatma
    Kebudi, Rejin
    [J]. TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY, 2013, 28 (01): : 44 - 50
  • [7] Bevacizumab for the treatment of high-grade glioma
    Khasraw, Mustafa
    Simeonovic, Marcelle
    Grommes, Christian
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (08) : 1101 - 1111
  • [8] Secondary Solid Malignancies After High-Grade Glioma Treatment in Pediatric Patients
    Karremann, Michael
    Hoffmann, Marion
    Benesch, Martin
    Kwiecien, Robert
    von Bueren, Andre O.
    Kramm, Christof M.
    [J]. PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2015, 32 (07) : 467 - 473
  • [9] STRUCTURAL VARIANT DRIVERS IN PEDIATRIC HIGH-GRADE GLIOMA
    Dubois, Frank
    Shapira, Ofer
    Greenwald, Noah
    Zack, Travis
    Tsai, Jessica W.
    Harutyunyan, Ashot S.
    Kumar, Kiran
    Sinai, Claire
    Malkin, Hayley
    Jones, Robert
    Ho, Patricia
    O'Rourke, Ryan
    Kang, Kyung S.
    Jabado, Nada
    Kieran, Mark W.
    Ligon, Keith
    Beroukhim, Rameen
    Bandopadhayay, Pratiti
    [J]. NEURO-ONCOLOGY, 2020, 22 : 351 - 351
  • [10] NOVEL EPIGENETIC TARGETS IN PEDIATRIC HIGH-GRADE GLIOMA
    Metselaar, Dennis S.
    Meel, Michael H.
    Waranecki, Piotr
    de Winter, Marcel
    Zwaan, Kenn
    van Vuurden, Dannis G.
    Kaspers, Gertjan L.
    Hulleman, Esther
    [J]. NEURO-ONCOLOGY, 2017, 19 : 24 - 24